MK 6592

Drug Profile

MK 6592

Alternative Names: MK-6592; VX-667

Latest Information Update: 22 Nov 2007

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck & Co
  • Class Antineoplastics
  • Mechanism of Action Aurora kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 20 Nov 2007 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
  • 01 Feb 2007 Phase-I clinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top